COMPLEMENTARY AND ALTERNATIVE MEDICINE
The group of agents and practices that falls outside of conventional western medicine is usually referred to as complementary and alternative medicine (CAM). There is varied opinion as to what practices and ideas fall under this broad term (Tascilar et al., 2006) . According to the National Center for Complementary and Alternative Medicine (NCCAM), a division of the National Institutes of Health in the United States, CAM is "a group of diverse medical and health care systems, practices and products that are not generally considered part of conventional medicine" (NCCAM, 2011) . NCCAM refers to conventional medicine as that which is practiced by individuals with either medical doctor or doctor of osteopathy degrees, along other health care professionals such as nurses, physiotherapists and psychologists (NCCAM, 2011) .
The Canadian Cancer Society (CCS) makes a clear distinction between the 'complementary' and 'alternative' components of CAM (CCS, 2010) . It defines complementary medicine similarly to NC-CAM as "any practice, therapy or product that is not considered conventional medicine for cancer care" (CCS, 2010) . Although many Canadian medical schools offer some training in complementary medicine practices, these practices are not conventionally used to treat cancer. Nevertheless, complementary medicine practices may be combined with standard patient care treatments to help alleviate side effects caused by cancer treatment (CCS, 2010) . However, alternative medicine by this definition is used instead of conventional, standard patient care treatments (CCS, 2010) . CCS emphasizes the fact that alternative therapies are often based on observations lacking any scientific base (CCS, 2010) . Regardless, most definitions of CAM refer to the same general principle of practicing wellness while being treated for a disease, and not necessarily adopting practices employed by conventional medicine.
The varied definitions assigned to CAM make interpretation of surveys on the use of these therapies difficult (Tascilar et al., 2006) . Nevertheless, many statistics have been published as to the prevalence of CAM in society worldwide. In a key systematic literature review of this topic, Harris and Rees reported that only three of the 12 studies they surveyed produced reliable prevalence data (Harris and Rees, 2000) . In a population survey, MacLennan and colleagues determined that nearly 50% of all South Australian residents used at least one non-medically prescribed CAM, whereas approximately 20% had sought help from a naturopath or other CAM practitioner (MacLennan et al., 1996) . This substantial prevalence of CAM is seen amongst all developed nations and has been increasing since the latter part of the 20th century. Between 1990 and 1997, the number of Americans that used CAM increased from 32 to 42%. Over the same period, patient inquiries about CAM to both medical doctors and CAM practitioners increased from 8 to 14% (Eisenberg et al., 1998; Eisenberg et al., 1993) . Currently, almost 4 out of 10 adults say they have used CAM in the past 12 months (Barnes et al., 2008) . This activity involves substantial expenditure that is also rising. Over the period 1997-2007, money spent on CAM-related therapies in the United States increased from just over $21 billion to nearly $34 billion (Eisenberg et al., 1998; Nahin et al., 2009) . Because Canadian statistics commonly mirror those of the United States, it is evident that many individuals seek benefit from CAM-related therapies (McFarland et al., 2002) .
Cancer patients are no less likely to use CAM. In a worldwide systematic review of 26 studies in 1998, approximately 31% of adult cancer patients were found to have used CAM therapies at some point after being diagnosed (Ernst and Cassileth, 1998) . This may be an underestimate for the more developed nations. The data are very variable depending upon geographical location, but more recent data from North America suggest that between 25 and 84% of cancer patients in the United States have used some sort of CAM therapy after their diagnosis (Tascilar et al., 2006) .
Arguably, the potential impact of ingested natural materials may be greater for cancers of the gastrointestinal tract. Tough and colleagues studied CAM use among colorectal cancer patients in Alberta (Tough et al., 2002) . The overall prevalence was 49% and the form of CAM use included psychological and spiritual therapies (65%), vitamins and minerals (46%) and herbal supplements (42%) (Tough et al., 2002) . Thus, although noninvasive practices (e.g., psychosocial and spiritual therapies) are most frequently associated with CAM, ingestion or topical application of biological substances accounts for a large portion of CAM use. The use of biological products in cancer has also risen significantly since the early 1990s (Cassileth and Deng, 2004; Cauffield, 2000; Molassiotis et al., 2005) . Because each of these substances has the potential to interact with conventional chemotherapeutic agents, it is important to analyze the consequences of using CAM-related biological substances while receiving chemotherapy.
ALOE: ITS HISTORY AND USE IN MEDICINE
Aloe is a genus of perennial succulent plants that thrive in hot, dry climates (Choi and Chung, 2003; Molassiotis et al., 2005) . Although there are nearly 400 species within the Aloe genus, only A. barrbadensis (also known as A. vera) and A. aborescens are used in therapeutic preparations (Moghaddasi and Verma, 2011) .
Aloe grows in temperate or tropical areas throughout the world (Moghaddasi and Verma, 2011) . It is a common and popular ornamental plant that can survive indoors or in gardens with scarce water supply. Large, agricultural-scale crops of Aloe are usually restricted to favored geographic areas such as Mexico, Africa, India, Australia and some parts of the United States (Florida, along with southern areas of Texas and California) (Moghaddasi and Verma, 2011) .
Originally described in the Ebers Papyrus, an ancient Egyptian book of remedies, Aloe was used in antiquity for treating skin infections and constipation (Ulbricht et al., 2007) . In 74 AD, the Greek physician Dioscorides documented Aloe as being useful for treating wounds, hair loss, genital ulcers and hemorrhoids (Ulbricht et al., 2007) . Several hundred years later on, Arab traders brought Aloe to Asia, and the Spanish introduced it to the Americas in the 16th Century (Ulbricht et al., 2007) . The popularity of Aloe rose dramatically in the 1930s as it became used as topical treatment for various forms of dermatitis (Reynolds and Dweck, 1999; Ulbricht et al., 2007) . Since the 1930s, Aloe has been incorporated in a multitude of cosmetic, dermatologic and other healthcare products (Reynolds and Dweck, 1999; Ulbricht et al., 2007) . However, it is also sold on its own as a therapeutic product, largely due to its roots in traditional medicine.
Following its established record of its use in folk medicine, Aloe is used for a variety of (sometimes contradictory) purposes. Based upon its use in traditional Chinese, Indian (Ayurvedic) and Arab medicine, Aloe is often used to treat constipation (Ulbricht et al., 2007) . However, Ayurvedic medicine also indicates that Aloe can be used to regulate menstruation, treat hemorrhoids, rid the body of parasitic worms, and when combined with licorice root, Aloe can be effective against eczema and psoriasis (Ulbricht et al., 2007) . Traditional Arab medicine, meanwhile, claims Aloe to be effective in the treatment of headaches, fevers, wounds and various forms of infection (Ulbricht et al., 2007) . Aloe is a truly versatile plant, if history is our guide.
THE DIFFERENT COMPONENTS OF ALOE
As evident in Fig. 1 , Aloe is a succulent plant with long, fleshy leaves. Parenchymal gel from the center of each leaf can be dried (resulting in Aloe concentrate) or can be diluted with water to make juice products. A sticky, latex-like liquid may also be extracted from the tubules that line each leaf (Moghaddasi and Verma, 2011) . Until 2002, when the United States FDA deemed it to be a class III substance such that a prescription or license is needed for legal possession, aloin (responsible for Aloe's laxative effects, due to aloin's anthraquinone moiety (Patel et al., 1989) ) was used in many over-the-counter laxatives. Today, manufacturers commonly remove aloin from Aloe preparations due to its potential side effects and insufficient safety data (NCCAM, 2011; Ulbricht et al., 2007) .
Fig 1
An Aloe vera plant. Note the long, fleshy leaves and the pendulous flowers on a central spike. Modified from (Bianchi, 1997) .
Given the consumer demand and commercial potential for Aloe products, researchers have begun to investigate the biological activity of Aloe leaf components. In part, such investigations seek to validate the claims made by CAM practitioners and the companies producing Aloe products, that Aloe is effective against a variety of diseases. Even a simple online search with "Aloe products" as the keyphrase will identify a variety of websites selling Aloe products for both internal and external use. In this review, our interest focuses on the potential use against cancer. Therefore, we will focus on the particular components of the plant that have been investigated for their anticancer activities.
Aloe contains many different classes of nutrient and modulatory chemicals (Table 1) . Attention has particularly focused on the anthraquinones, a class of agents renowned for their various bioactivities (Choi and Chung, 2003) . In cancer research, the most widely studied pharmacologically active anthraquinones are aloe-emodin and aloin (Choi and Chung, 2003; Manitto et al., 1990; Reynolds and Dweck, 1999) . Both of these compounds can be isolated from the latex leaf lining of Aloe plants (Moghaddasi and Verma, 2011) . Aloin and aloe-emodin are structurally related (Fig. 2 A, B) . Whereas aloeemodin's structure has two carbonyl (C=O) groups, the replacement of one carbonyl group with a glucose residue leads to the structure of aloin. Aside from the anthraquinones, some anticancer studies have investigated the saccharide components of the Aloe plant. These have primarily focused upon acemannan, a hydrophilic sugar polymer (Fig.  2 C) . Acemannan is a polymer of 3-O-acetyl-β -D-mannopyranose (acetyl-mannose) units linked by β -1→4 glycosidic bonds. Amongst Table 1 Major families of biologically-active chemicals in Aloe. the low-molecular-weight substances that have been identified within Aloe is b-sitosterol, one of several phytosterols (plant sterols) that has a structure very similar to that of cholesterol (Fig. 2 D) . This review will focus upon the reported anti-cancer activities of these four principal components: Aloe-emodin, aloin, acemannan and bsitosterol. Many different potential cellular effects have been noted in an array of experimental systems; some of the more significant recent findings are summarised in Table 2 . There is a great diversity in terms of available information (e.g. the cellular sources studied and the assays used) and considerable disparity in the amount of data for different Aloe constituents (e.g. there are 18 different studies on aloe-emodin, and just a single relevant study for acemannan). There is also substantial variability in the sources of the materials tested, the degrees of purity and the active concentrations tested. It is therefore important to understand the full picture of activities that have been identified (Table 2) .
Chemical family Examples

POTENTIAL ACTIVITIES OF ALOE COMPONENTS IN CANCER
Activities of Aloe-emodin
Aloe-emodin has been heralded as a novel potential chemotherapeutic drug due to its ability to modulate the cell cycle and cell proliferation, effects that are mediated by the action of aloe-emodin on protein kinases C (PKC) a family of 10 signaling enzymes that are important in the release of hormones, cell division and tumor growth (Acevedo-Duncan et al., 2004; Blobe et al., 1994) . Human glioma cells exposed to aloe-emodin were unable to progress through the DNA synthesis phase (S phase) of the cell cycle and cell proliferation was inhibited (Acevedo-Duncan et al., 2004) . The activity of all PKC isozymes except PKC-ι (the isozyme related to protection of a cell against apoptosis) decreased upon exposure of the cells to aloeemodin. Aloe-emodin concurrently increased the tendency of cells to enter apoptosis (a form of programmed cell death) by modulating the balance of peptidases that promote apoptosis (e.g., caspase-7) and the apoptosis inhibitor survivin (Acevedo-Duncan et al., 2004) .
Investigations in cells from a variety of neoplasias show a consistent action of aloe-emodin in inhibiting cell proliferation and enhancing apoptosis through pathways involving PKC. In human lung squamous Table 2 Potential anti-cancer activities of the key biologically-active compounts in Aloe vera.
Compound Type of cancer Experimental Model* Potential Anticancer Action(s)
Aloe-emodin Oral cavity KB cell line G2/M cell cycle arrest; enhanced alkaline phosphatase (ALP) activity (Xiao et al., 2007) . Tongue SCC4 cell line Enhanced apoptosis and S-phase cell cycle arrest (involvement of mitochondrial death pathways, caspase cascades and the Fas/death-receptor) (Chiu et al., 2009 ).
SCC4 cell line Decreased cell migration and invasion (suppression of MMP-9 gene expression; decreased protein levels and activity of MMP-2, but no change in MMP-2 gene expression) (Chen et al., 2010a) .
SCC4 cell line
Increased DNA damage and decreased DNA repair (inhibition of DNA repair genes -MGMT, ATM, ATR, BRCA1, 14-3-3sigma, DNA-PK) (Chen et al., 2010b) .
Pharynx NPC-TW039 and Increased apoptosis (caspase-8 activation of mitochondrial death pathways); enhanced G2/M NPC-TW076 nasopharyngeal phase cell cycle arrest (increased CyclinB1/Cdc2 binding) (Lin et al., 2010) . AGS and NCI-N87 cell lines Enhanced apoptosis (mitochondrial release of apoptosis-inducing factor and cytochrome c, subsequent caspase-3 activation); reduced phosphorylation of pro-apoptotic BH3 interactingdomain death agonist, BID (Chen et al., 2007) .
Liver Huh-7 hepatoma cell line Decreased proliferation; induced apoptosis (decreased expression of calpain-2 and ubiquitinprotein ligase E3A) (Jeon et al., 2012) .
HepG2, HCCM and Hep3B
Induced apoptosis (increased oxidative stress and decreased intracellular reduced glutathione hepatocellular carcinoma (GSH); prolonged activation of c-Jun N-terminal kinase (JNK) and involvement of apoptosis cell lines signal-regulating kinase-1) (Lu et al., 2007a) .
Colon
WiDr cell line Angiogenesis inhibitor (suppressed vascular endothelial growth factor (VEGF) expression and migration/invasion of endothelial cells); reduced mRNA levels of matrix metalloprotease-2/9
and RhoB; decreased nuclear translocation and DNA binding of transcription factor (NF-KB) responsible for VEGF and MMP-2/9 expression (Suboj et al., 2012) .
Cervix
HeLa cell line G2/M cell cycle arrest (reduced cyclin 2 And CDK2 levels; Increased cyclin B1 and CDK1 levels); reduced PKC-alpha and c-myc expression (Guo et al., 2007) .
Bladder T24 cell line Enhanced G2/M cell cycle arrest (decreased cyclin-dependent kinase 2 and cyclin B1 levels); apoptosis (increased p53 expression, p21 and caspase-3 activation; enhanced Fas/APO1 receptor and Bax expression) (Lin et al., 2006) . Skin B16-F10 murine melanoma Inhibited proliferation, migration; decreased invasion (suppressed MMP-9 secretion); cell line enhanced cell differentiation, adhesion and aggregation (Tabolacci et al., 2010) .
A431 epidermal carcinoma
Increased apoptosis (upregulation of tumor necrosis factor (TNF)-alpha and Fas ligand, cell line; SCC25 head and neck their respective receptors and adaptor domains; caspase-8 activation, among other squamous cell carcinoma molecular events associated with apoptosis); aloe-emodin combined with 5-fluorouracil cell line enhanced cell death by activation of multipie caspases (Chou and Liang, 2009 ).
Lung H460 large-cell lung carcinoma Photoactivated aloe-emodin induced anoikis (cell death occuring when anchoragecell line dependent cells detach from the extracellular matrix) (Lee et al., 2010) .
H460 large-cell lung carcinoma Induced apoptosis; detected a change in 11 proteins (e.g., vimentin, ATP synthase and cell line endoplasmic reticulem chaperones); caspase-3 apoptotic pathway activation (Lai et al., 2007) .
Lymphoma
U937 cell line Enhanced transglutaminase activity resulting in differentiation of cells to mature monocytes, highlighting aloe-emodin's potential to be used for monocytic differentiation in leukemia therapy (Tabolacci et al., 2011) .
Pharynx, liver, FaDu pharyngeal squamous S-phase cell cycle arrest (cyclin-Cdk2-p21 complexes resulted from extracellular bone cell carcinoma cell line; Hep3B signal-related kinase (ERK) activation); promotes apoptosis by caspase-8-mediated hepatoma cell line; MG63 activation, independent of p53 involvement (Lin et al, 2011 Acemannan Leukemia Feline-leukemia virus-infected Intraperitoneal administration to clinically symptomatic cats resulted in enhanced cats survival and quality of life (Sheets et al, 1991) .
β-sitosterol Colon COLO 320 DM, human colon Inhibited growth, promoted apoptosis and decreased the expression of both betacancer cell line; male catenin and proliferating cell nuclear antigens (cell line); decreased aberrant crypt Wistar rats formation in 1,2-dimethyl hydrazine-initiated rats (Baskar et al., 2010) .
Stomach SGC-7901 cell line increased cytotoxity and decreased cellular proliferation; induced apoptosis (DNA damage, morphological changes, increased expression and activation of pro-caspase-3; Increased bax expression; decreased bcl-2 expression) (Zhao et al., 2009 (Awad et al., 2008) .
Leukemia U937 and HL60 cell lines Enhanced caspase-3 activation and increased DNA fragmentation; induced cell cycle arrest and endoreduplication (nuclear genome replication without cell division); increased polymeric alpha-tubulin levels and microtubule polymerization (effects mediated by PI3K/ Akt and Bcl-2 signaling pathways) (Moon et al., 2008) . with collagen I, collagen IV, fibronectin and laminin; prevented cell growth; induced G2/M cell cycle arrest (Awad et al., 2001 ).
Prostate
LNCaP cell line Increased activation of the sphingomyelin cycle (enhanced protein phosphatase 2 activity, without changes in its protein levels); possible activation of membrane-bound enzymes (Awad et al., 2000) .
* Human, unless otherwise indicated. (Awad et al., 2008; Awad et al., 2007; Awad et al., 2000; Awad et al., 2001; Baskar et al., 2010; Chen et al., 2007; Chen et al., 2010a; Chen et al., 2010b; Chiu et al., 2009; Chou and Liang, 2009; Esmat et al., 2005; Guo et al., 2008; Guo et al., 2007; Jeon et al., 2012; Ju et al., 2004; Koschutnig et al., 2009; Lai et al., 2007; Lee et al., 2010; Lin et al., 2006; Lin et al., 2010; Lin et al., 2011; Lu et al., 2007a; Moon et al., 2008; Moon et al., 2007; Niciforovic et al., 2007; Park et al., 2008a; Park et al., 2003; Sheets et al., 1991; Suboj et al., 2012; Tabolacci et al., 2010; Tabolacci et al., 2011; Xiao et al., 2007; Zhao et al., 2009 ). carcinoma and non-small cell carcinoma cell lines, aloe-emodin provoked apoptosis alongside a decrease in expression of two PKC isozymes (d and e) and an increase in the apoptosis effector caspase, caspase-3 (Lee, 2001). Similarly, emodin isolated from rhubarb (Rheum palmatum) and structurally similar to aloe-emodin induced apoptosis in a human leukemia cell line by means of a mechanism that depended on caspase-3 (Chen et al., 2002) . Therefore, aloe-emodin initiates PKC-dependent signalling pathways that lead to cell death in a variety of cancer cell lines.
Interestingly, aloe-emodin was able to hinder cell proliferation in one human liver cancer cell line (HepG2) and induce apoptosis in another (Hep3B) (Kuo et al., 2002) . Further dissection of the mechanism identified p53 and p21 as major players. In the HepG2 cell line, aloe-emodin exposure resulted in p53 expression that led to increased p21 expression. The protein p21 is a cyclin-dependent kinase inhibitor and interacts with cyclin-dependent kinases that regulate cell cycle progression at the G1 phase (Kuo et al., 2002) . The G1 checkpoint is when the cell interprets a number of incoming signals that determine whether or not it divides (Massague, 2004) . Consequently, increased p21 expression in HepG2 cells causes G1 cell cycle arrest. Additionally, aloe-emodin prevents DNA synthesis by upregulation of both p16 and retinoblastoma protein, two important tumor suppressor proteins (Lu et al., 2007b) .
However, Hep3B cells do not express p53 to trigger this cascade of events leading to G1 cell cycle arrest (Kuo et al., 2002) . In these cells, apoptosis was induced by increased expression of Bax, a proapoptotic protein that is regulated by p21 in a p53-independent manner (Kuo et al., 2002) .
Aloe-emodin has effects on other molecular targets in HepG2 cells. It upregulates proteins associated with oxidative stress and increases the amount of intracellular reactive oxygen species (Lu et al., 2007b) . Furthermore, aloe-emodin inhibits cell migration by upregulating nonmetastastic gene 23, an important metastasis inhibition factor (Lu et al., 2007b) . Upregulation of the Fas receptor, a member of the tumor necrosis factor (TNF) receptor family, on HepG2 cells has been documented as well (Jiang et al., 1999; Kuo et al., 2002) . Fas modulates apoptosis upon binding FasL, its endogenous ligand (Jiang et al., 1999; Kuo et al., 2002) . This response leads to mechanisms that overlap with those triggered by conventional chemotherapeutic drugs.
The data on selective toxicity of aloe-emodin against different cancers are somewhat contradictory because they demonstrate activity of aloe-emodin against some experimental cancer cell lines within a tumour type, but not others. Some studies are highly encouraging. In one study for example (Pecere et al., 2000) , aloe-emodin was found to be active against neuroectodermal tumor cells in both tissue culture and animal models, and caused cell death (e.g., cell shrinkage, membrane blebbing and nuclear fragmentation were observed -all of which are morphological features of apoptotic cells). However, growth of human hematopoietic progenitors and normal fibroblasts was not inhibited by aloe-emodin (Pecere et al., 2000) . In fact, hematopoietic cells were not affected at concentrations more than 100 times higher than those required to inhibit neuroectodermal tumor cell growth (Pecere et al., 2000) . This observation is especially important because high-dose chemotherapy is often associated with neutropenia, a dose-limiting toxicity (Lyman et al., 2005) . In severe combined immunodeficiency (SCID) mice, there was no evidence of acute or chronic toxicity of aloe-emodin injected subcutaneously at the highest concentration that could be dissolved in an aqueous solution (50 mg/kg/day) (Pecere et al., 2000) . Unfortunately, in the same study, it was also found that aloe-emodin failed to inhibit the growth of epithelial and bloodderived tumor cell lines (e.g., T-cell leukemia, colon adenocarcinoma and cervix epithelial carcinoma cells), suggesting that any selectivity is based upon cell type rather than whether the target cell is normal or malignant (Pecere et al., 2000) .
Of significant concern are observations that in certain circumstances, aloe-emodin may enhance tumor cell growth. For example, it was found to increase the growth of colorectal carcinoma cells (Schorkhuber et al., 1998) . After chemical modification by intestinal bacteria, aloe-emodin becomes a strong laxative (Schorkhuber et al., 1998) . Continued use of laxatives containing aloe-emodin has been associated with many adverse side effects, including the risk of developing colon cancer in experimental models (Muller et al., 1996; Schorkhuber et al., 1998) . It has been suggested that one detrimental action of aloe-emodin might be its ability to increase secretion of urokinase, an enzyme that can digest extracellular matrix, which can increase cell proliferation and, in the context of neoplasia, could also promote metastasis from the colon (Schorkhuber et al., 1998) .
Whereas Aloe components (most notably aloe-emodin) have been shown by Ames testing to possess mutagenic and possible carci-nogenic potential in vivo, animal studies have not yet unanimously demonstrated these findings (Brusick and Mengs, 1997; Mueller et al., 1998) . It has also been suggested that aloe-emodin might be genotoxic by hindering the interaction of topoisomerase II with DNA (Muller et al., 1996) . Although topoisomerase II inhibition as such is a cytotoxic mechanism exploited by anti-cancer drugs such as etoposide, improper topoisomerase II function may lead to mutations and chromosomal translocations as have been observed in some forms of leukemia (McClendon and Osheroff, 2007; Muller et al., 1996; van Maanen et al., 1988) .
Although many researchers believe that laxatives containing aloeemodin may increase an individual's risk of developing colorectal cancer, other data from human studies show no significant risk of long-term (up to 20 years) laxative use (Nusko et al., 2000) . Therefore, it is not conclusive that aloe-emodin-containing laxatives may increase the risk of developing colorectal cancer. Indeed, it is possible that they may instead play a protective role through their suppressive effects on N-acetyltransferases (NATs). NATs are responsible for catalyzing metabolic cascades induced by acrylamine compounds, such as those found in cooked meat . Through their bioactivation (involving N-acetylation reactions) and detoxification pathways (involving O-acetylation reactions), these enzymes create intermediate metabolites capable of forming adducts with DNA, which can lead to various forms of cancer . Aloe-emodin decreases NAT activity, likely by binding to the enzyme-substrate complex inhibiting NAT activity as a possible non-competitive inhibitor. The net effect is to hinder the formation of DNA adducts after acrylamine exposure .
Several studies have tried to quantify the levels of aloe-emodin that can be attained within the human body and therefore interact with cells following ingestion. Therapeutic doses of laxatives containing aloe-emodin administered repeatedly in 10 healthy volunteers resulted in aloe-emodin being undetectable in blood samples collected within 96 h of receiving the first dose (Krumbiegel and Schulz, 1993) . A kinetic study using two in vitro intestinal models -an everted rat gut sac and a monolayer of differentiated and absorptive cells similar to those in the small intestine (Caco-2 cells) also tried to determine the fate of aloe-emodin when ingested (Park et al., 2009 ). Uptake of aloe-emodin by intestinal epithelial cells was demonstrated by both approaches. After incubation with 5 to 50 µM of aloe-emodin, the rate of aloe-emodin absorption was similar between the two models, and reached saturation near the 50 µM treatment. The percentage of aloe-emodin that was absorbed ranged from 6.6% to 11.3% (Park et al., 2009 ) This ready uptake is likely due to aloe-emodin's relatively high affinity for phospholipid membranes (Park et al., 2008b) . In addition, aloe-emodin may interact with certain transporters, such as the sodium dependent glucose transporter-1 that could transport aloe-emodin into the cell unchanged (Park et al., 2008b) . Additionally, Caco-2 cells may metabolize aloe-emodin by phase II metabolic reactions involving glucuronidation or sulfation and in this context it has been found that nearly 19% of glucuronidated or sulfated aloeemodin was absorbed (Park et al., 2009) . Metabolism in vivo is mostly in the liver, and aloe-emodin can be converted to 2-hydroxyemodin by cytochrome P450 1A2 (Mueller et al., 1998; Park et al., 2008b) .
Whereas aloe-emodin has been studied for its ability to regulate cell cycle and proliferation through its interaction with a variety of molecular targets, literature underlining aloe-emodin's potential carcinogenic effects make it unclear as to whether or not this compound can be used for its anticancer properties. However, research associated with aloin, and anthraquinone similar to aloe-emodin, has also been conducted.
Activities of Aloin
Aloin (Fig. 2 B) is a mixture of two diasteromers, aloin A and aloin B, which differ depending on whether the sugar moiety is above (aloin A) or below (aloin B) the plane of the anthroquinone (Park et al., 2008b) . Because aloin can be converted to aloe-emodin anthrone by intestinal bacteria in humans, these two compounds share similar biological effects after ingestion, such as their abilities to act as potent laxatives (Akao et al., 1996) (Choi and Chung, 2003) . Whereas the majority of anticancer research has focused on the pharmacological effects of aloe-emodin, several anticancer properties of aloin have also been investigated.
Just as for aloe-emodin, aloin has been linked with the ability to trigger apoptosis. Using Jurkat T-lymphocytes, aloin was shown to disrupt cell membrane integrity and interfere with mitochondrial membrane potential, both of which are hallmarks of apoptosis (Buenz, 2008) . Using DNA-staining techniques, aloin was also found to increase the proportion of cells at the G2 cell cycle phase that precedes cell division (Buenz, 2008) . These apoptotic and antiproliferative effects required large doses within the range of 100 -1000 µg/ml. The huge variabiity in doses of aloin (or other agents) may reflect the absence of enzymes that may convert aloin to active metabolites, which are often found in the liver. However, more studies are required to not only determine, but also characterize aloin metabolites in vivo and in vitro (Buenz, 2008) .
Aloin has been shown to be cytotoxic in two human breast cancer cell lines (MCF-7 and SKBR-3) (Esmat et al., 2006) . Similar to aloeemodin, there seems to be a link with topoisomerase II, and also with the HER-2/Erb-2 oncogene, which specifies an aberrant growth factor receptor. Topoisomerase IIa and HER-2/Erb-2 genes are often coamplifed in breast cancer, and the amplification of topoisomerase IIa together with HER-2/Erb-2 relates to the effectiveness of aloin action (Esmat et al., 2006) . MCF-7 cells (with no overexpression of either Erb-2 or topoisomerase IIa) were more sensitive to the cytotoxic effects of aloin (half-maximal inhibitory concentration (IC 50 ) 60 µg/ml, compared with 150 µg/ml) than SKBR-3 cells (with coamplification of Erb-2 and topoisomerase IIa) (Esmat et al., 2006) . The effect of aloin in MCF-7 cells was to disrupt the cell cycle and induce apoptosis by inhibiting cyclin B1 (a regulatory protein in mitosis) expression, following inhibition of topoisomerase IIa expression (Esmat et al., 2006) . SKBR-3 cells exhibited a lesser effect consistent with the slight decrease in topoisomerase IIa expression. Clearly, the effect of aloin on breast cancer cells depends on the precise phenotype of the cancer cells. It also appears that this compound exerts its action through a variety of mechanisms.
The intestinal epithelial absorption of aloin in everted rat gut sac and Caco-2 cell models is similar to that of aloe-emodin, even though there is no bacterial conversion to the latter in these systems. The absorption of aloin was between 5.5% and 6.6%, with approximately 18.2% being absorbed if in the glucuronidated or sulfated form (Park et al., 2009) . To assess aloin's bioavailability in vivo, plasma, tissue and urine concentrations of aloin were measured in rats that were given 11.8 g/kg of aloin by gavage (Park et al., 2008b) . This dose was chosen based on previous studies that had established 11.8g/kg as the lowest observed adverse effect level. Aloin was detected in the plasma, with its peak concentration (59.1 ng/ml) being reached after 1h. Aloin reached its peak liver and intestine concentrations in 30 min, with the liver concentration being approximately 78 ng/ml and that of the intestine being roughly 100 ng/ml. The peak kidney concentration (nearly 13 ng/ml) occurred after 5h and the amount of aloin that had accumulated in the urine over a 24-h period was estimated to be 0.03% of the initial dose (Park et al., 2008b ). Metabolism appears to be primarily hepatic (Park et al., 2008b) .
The studies using both aloe-emodin and aloin show a substantial disparity between the concentrations that are tested in vitro to identify putative anti-cancer effects, and those that are attainable in vivo even with generous oral dosing. The work of Park and colleagues (Park et al., 2008b) , with oral dosing that would equate to a daily intake of 0.83 kg of aloin per day in the standard 70kg human, yielded systemic levels of no more than 100 ng/ml. Yet some of the in vitro studies with cancer cell lines have used concentrations in culture as high as 1000 µg/ml (Buenz, 2008) , that is 10,000-fold higher than are readily attainable. While the use of anthraquinones at such high concentrations in culture may reveal useful activities of molecular motifs that could be refined to eventually produce a worthwhile drug, it has very little value in informing us of the value of Aloe itself if ingested by an actual cancer patient. More focused efforts on the application of Aloe components are underway: investigations are being conducted to compare aloin's cardiotoxicity to that of commonly used chemotherapeutic agents such as doxorubicin, an anthracycline that often induces cardiotoxicity (Esmat et al., 2006) ; and researchers are attempting to modify aloin's chemical structure in order to heighten its cytotoxic effects (Kumar et al., 2010) .
Activities of Acemannan
Acemannan, which is isolated from the gel of the Aloe plant, has been shown to activate macrophages both in vitro and in vivo (Djeraba and Quere, 2000; Moghaddasi and Verma, 2011; Zhang and Tizard, 1996) , and might therefore potentially promote the action of tumourassociated macrophages. Acemannan binds to protein receptors on the macrophage cell surface (Djeraba and Quere, 2000; Zhang and Tizard, 1996) , facilitating the internalization of acemannan, which in turn results in macrophage activation. Such activation is associated with the release of cytokines that have many actions, including the enhancement of T-cell proliferation and increased T-cell-mediated cytotoxicity (Djeraba and Quere, 2000; Karaca et al., 1995; Zhang and Tizard, 1996) .
Macrophage activation is often measured in terms of nitric oxide (NO) production (Djeraba and Quere, 2000; Karaca et al., 1995; Zhang and Tizard, 1996) . NO regulates major histocompatibility cell (MHC) surface antigens that are required for antigen presentation and the recognition of foreign antigens, such as those that may be present on a cancer cell (Djeraba and Quere, 2000; Zhang and Tizard, 1996) . Furthermore, release of NO has been shown to inhibit the DNA synthesis of tumor cell lines (Drapier and Hibbs, 1988) .
Although mechanisms of acemannan action are still being investigated, it appears that acemannan principally functions to enhance immune mechanisms (e.g., macrophage activation, immune system stimulation and enhanced release of anticancer cytokines) (de Visser et al., 2006; Harris et al., 1991; Peng et al., 1991) . This has proven sufficient grounds for it to be used in the treatment of cancer in animals such as cats and dogs (Harris et al., 1991; VPL, 2011) . The compound is typically administered by subcutaneous or intramuscular injection, and it is uncertain whether oral doses would be as effective (VPL, 2011) . Oral acemannan needs to be broken down by gut flora so that mannose receptors lining gut epithelial cells can transport it into the bloodstream for distribution throughout the body (Flint et al., 2008) .
Activities of b-sitosterol
Aloe plants contain numerous other components that may exert effects on cell cycle and proliferation. For example, Aloe gel also yields b-sitosterol, which is partly responsible for Aloe's wound healing properties and has been demonstrated to be a potent inducer of angiogenesis (Choi et al., 2002; Lee et al., 1995) . This is thought to occur by the ability of b-sitosterol to increase pro-angiogenic proteins such as vascular endothelial growth factor (VEGF), Flk-1 (a receptor for VEGF), von Willebrand factor and blood vessel matrix laminin (Choi et al., 2002) . Because angiogenesis is an essential step in tumour progression since tumors require a blood supply to grow larger or spread to other organs, there is a possibility that b-sitosterol may promote tumor growth in animal models (Carmeliet and Jain, 2000) .
USE OF ALOE IN TREATMENT OF HUMAN CANCERS
Aloe use, whether for topical purposes or by ingestion, has been a well-established practice in different cultures for many years. Therefore, it is no surprise that even with conflicting reports as to the proposed biological activities of Aloe components and suggestions of interactions of these components with anticancer drugs, cancer patients will continue to use Aloe or its components. This may be for hoped-for anti-cancer properties, or to alleviate symptoms of conventional therapies. For example, at the time of writing one website for a company that markets Aloe products makes these comments "Courses of chemotherapy tend to make people feel thoroughly rotten. This particular treatment tends to cause bouts of nausea that negates what little appetite they might have. Drinking gel before, during and after chemotherapy may alleviate these symptoms." (FLAP, 2010).
Evidence for Anti-cancer Activity
There have been several clinical studies that have looked at possible effects of Aloe in addition to standard chemotherapy. One focused study looked at its use in lung, colorectal, gastric and pancreatic cancer patients in addition to a base of standard-of-care chemotherapy appropriate for the clinical characteristics of each metastastic, solid tumor (Lissoni et al., 2009) . A comparison was made between patients who received Aloe in addition to their chemotherapy and patients who did not receive Aloe with their chemotherapy. For patients that received Aloe, an oral dose was given three times each day, beginning six days before the onset of chemotherapy. Aloe administration was continued during chemotherapy and each dose consisted of 300 g of fresh Aloe leaves together with 500 g of honey. It was found that Aloe given in conjunction with chemotherapy significantly increased tumor regression and disease control, while also prolonging survival (Lissoni et al., 2009) . Furthermore, quality of life increased in patients that received both Aloe and chemotherapy because of decreased asthenia (loss of strength) and increased energy levels (Lissoni et al., 2009 ). However, this study was not blinded -and it would be hard to blind such a treatment -so that confounding influences such as altered patient behaviour in the treatment group are hard to exclude.
The same investigators also conducted a controlled clinical trial on patients with numerous advanced solid tumors that were refractory to established treatment (Lissoni et al., 1998) . In this case, patients were given either melatonin (an immunomodulating hormone produced by the pineal gland) or a combination of melatonin and Aloe. Improvements were reported for the combination of melatonin and Aloe compared with melatonin alone, in partial response (8% vs 0%), stable disease (50% vs 27%) and one-year survival rates (Lissoni et al., 1998) .
There is thus some evidence of a beneficial effect of Aloe in advanced cases of human cancer (Lissoni et al., 1998; Lissoni et al., 2009 ). However, it will be necessary to carry out blinded and randomized trials with at least partially-purified extracts before the evidence is fully convincing.
Possible Interactions with Conventional Drugs
Because numerous chemotherapeutic drugs (e.g., cisplatin, 5-fluorouracil (5-FU), adriamycin, mitoxanthrone and etoposide) have been found to induce apoptosis in solid tumors and some types of leukemia, some researchers believe it is possible that aloe-emodin may be useful in enhancing their apoptotic response (Fenig et al., 2004; Hickman, 1992; Jiang et al., 1999) . However, data relating to this belief are somewhat contradictory because some studies document a cytoprotective effect of aloe-emodin. For example, aloe-emodin reduced cisplatin's ability to trigger apoptosis in certain fibrosarcoma and glioma cell lines (Mijatovic et al., 2005) . In these cells, aloe-emodin in fact interfered with cisplatin's ability to activate the extracellular signal-related kinase (ERK) pathway that can promote apoptosis or cell cycle arrest (Cagnol and Chambard, 2010; Mijatovic et al., 2005) . The cytoprotective action of aloe-emodin was further examined in comparable fibrosarcoma and glioma cell lines (Harhaji et al., 2007) . It was determined that aloe-emodin reduced the cytotoxic effects of TNF, a proinflammatory cytokine, by decreasing TNF-initiated ERK activation (Harhaji et al., 2007) . Therefore, the possibility exists, that aloe-emodin can interfere with conventional drug therapy in addition to having the potential to enhance anti-cancer drug action. This poses something of a dilemma in terms of arguments for a therapeutic effect of ingested aloe-emodin in cancer patients.
Assessment for Dermatologic Benefit
Perhaps more inherently logical given the wide utility of Aloe in skin care products is the possibility of using Aloe to address dermatological problems incurred during cancer treatment. Aloe gel has been evaluated as a possible agent to prevent dermatitis caused by radiation therapy (Williams et al., 1996) . In a first Phase II randomized clinical trial, these investigators tracked the status of skin dermatitis (e.g., severity of dermatitis, time until severe dermatitis occurs and how long severe dermatitis would persist) in female patients receiving chest or breast radiation treatment. It compared the topical applica-tion of Aloe to a placebo gel and found no significant differences between the treatment groups. A second trial was conducted with a similar patient cohort to eliminate the possibility that the gel itself might be efficacious, and compared an Aloe gel group against a 'no treatment group'. However, this trial also failed to demonstrate an effect of Aloe, indicating that the dermatitis resulting from radiation therapy (which has a large component of direct cellular damage) is not alleviated by Aloe product. Therefore, these studies would suggest that Aloe is ineffective for dermatological problems associated with cancer treatments.
FUTURE PROSPECTS FOR ALOE IN
CANCER TREATMENT
Is Aloe Useful for Cancer Treatment?
The situation with Aloe is similar to that of many natural products that have garnered an active following in the general population that arises out of a long history of use extending back to before the emergence of western medicine. It has proven extremely challenging to show effects that will satisfy the demands of evidence-based medicine. Bench science using experimental models has revealed promise for bioactivity of individual components of Aloe, but the evidence is often flawed by the use of doses that are many orders of magnitude above those attainable in the human patient. Research in both cellular and animal models has also suggested possible negative actions of these compounds, leading to toxicities or perhaps even increased cancer risk. This research again may be compromised by the experimental doses, but it is an inevitable truth that any substance that has useful bioactivity will carry a risk of 'off-target' side effects as a result of its activity; there is no assurance that just because something 'is natural' it cannot also be harmful.
Whether or not natural components of Aloe have genuine activity against cancer (or potentially may promote aspects of the disease) is unclear based on both the in vitro and clinical data presented in this review. However, it is evident that -as for many natural sources -the native molecules do have activities against cellular pathways that if appropriately extended, could lead to useful agents to manipulate the cellular response.
Identifying the chemicals within Aloe that might have potential for further study or development will require thorough studies that characterize the wide variety of potentially biologically active compounds of the plant. Each of these compounds must be assessed for their effects on cell cycle proliferation. Furthermore, it is likely that interactions between these compounds also influence their respective biological activities.
Safety in Use of Aloe
Aloe is a popular biologic used by the public in CAM-related approaches to disease treatment, and there are many companies producing Aloe products. It is important for the public to recognize that the composition of these products is highly variable, especially when Aloe extracts are obtained from plants of different geographic origins (Choi and Chung, 2003; Reynolds and Dweck, 1999) . There are often poor manufacturing techniques and quality control mechanisms in place to ensure standardized forms of Aloe preparations (Choi and Chung, 2003; Moghaddasi and Verma, 2011; Reynolds and Dweck, 1999) . Additionally, poor regulation of Aloe products has prevented CAM practitioners from agreeing on a standard dose that can be efficacious without inducing undesirable side effects (Marcus and Grollman, 2002) .
These again are common challenges in the use of whole natural products to self-treat disease. Understanding the biological activities of Aloe constituents, their interactions with conventional medicines, and proper standardization of product content, are essential for the safety of those who take these preparations, irrespective of the contribution they make to alleviating disease.
